Ichan didn't sell out in the low $30s for no good reason.
A couple bucks vs. what on thedownside..double or triple that? I don't see it. You stayed too long at the party , and when the sun comes up , the hangover will be fierce and your bad judgement will become clear to you.
Beware the Ides of March if you are short.
Patience, little weedhopper.
Our day will come.
Nothing wrong with this company that can't be/ hasn't already been fixed, and the price is right.
Go buy Facebook if you like to buy high.
Re: Mobile problem for WBMD:
[excerpted from VIC (bear) writeup:
Shift to mobile will be detrimental to WBMD’s fundamentals
◦ While overall page views for the company are still growing, mobile has been driving desktop page views down 10-20% the last three quarters
▪ This has yet to impact ad buying decisions, but if traffic continues to be impacted negatively, we expect that this will impact further the company’s already weakened negotiating position relative to advertisers as their premium inventory becomes worth less
◦ The bull argument is that mobile represents remnant inventory that will be valuable once they figure out how to monetize it
▪ Simplistically, mobile devices (particularly smartphones) are too small of a form factor for pharma advertisers to adequately display their products as well as the necessary disclosures mandated by the FDA
▪ They are currently only monetizing slightly via consumer product companies, which is a small opportunity
▪ The company fully admits that they are unable to monetize mobile in any meaningful way with pharmaceutical companies due to these limitations, despite having popular mobile apps
▪ They first launched mobile apps in Q408, so they've been trying for almost 5 years
▪ Investors in most startups that have been around for 5 years generally have a reasonable understanding of whether the strategy will work or not
Explain to me how the drug ads (with all that govt. required teeny-tiny print about side effects) works
well on mobile devices. Mobile diminishes them greatly.
Icahn got out for a reason, duh.
Actually, SNMX was posted as a best idea for 2014 at the same site (VIC) around the first of January by the same writer and garnered some interest back then. These analysts there are mostly very sharp guys, posting ideas (under screen names, so as not to mix their jobs up with this after hours activity), and are competing with one another for posting the best ideas..so it's a pretty good resource for hunting for value, mostly obscure stock ideas.
You still short? I think that idea was great early last year.... getting married to your positions is a classic mistake, but a common one. Good luck with that. AH has much more upside potential than downside. Once the restatements are made, all the fears will be out of the closet, the shorts will cover and new longs will come jump into this, including lots of institutional buyers. I would not want to be a an old, stale-news greedy short hoping to pick up a few more nickels in front of an oncoming steamroller... But, that's just me.
I want to correct what I wrote above about the resume of (Director) Alex Mandl - Actually he never was the CEO or Chairman of AT&T - he was, in fact, their COO, and was in line to be CEO and Chairman, by all accounts, but walked away to start Teligent (which later failed). So, he does have a mixed track record, but, still,
Alex Mandl is a new Director. He's a former CEO & Chairman of AT&T, so has a little bit of experience managing large companies that have issues (which don't?). I guess he knows less about AH than, and business in general, than you?